Toward a new standard in MS disease control


REVIEWER: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

Redefining therapeutic efficacy

New data on novel and emerging therapies were the centrepiece of the 2014 joint meeting of the Americas and European Committee for Research and Treatment of Multiple Sclerosis (ACTRIMS/ECTRIMS), with results suggesting that clinical standards are being redefined for optimal disease control in relapsing-remitting multiple sclerosis (RRMS).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page